Evercore ISI has upgraded CRISPR (CRSP) to outperform from in line, citing upcoming data catalysts. Read more here.

Evercore ISI analysts upgraded CRISPR Therapeutics stock from an In Line to an Outperform rating and increased the price target significantly to $99 from the previous $60. The upgrade comes as ...

Evercore ISI analyst Liisa Bayko raised the price target for CRISPR Therapeutics from $60.00 to $99.00. Bayko's optimism is driven by upcoming catalysts that could mark a new chapter for the company.

Confluent (NASDAQ:CFLT – Get Free Report) had its target price upped by Evercore ISI from $32.00 to $40.00 in a report ...

Confluent (NASDAQ:CFLT – Get Free Report) had its price target boosted by investment analysts at Guggenheim from $35.00 to $38.00 in a note issued to investors on Wednesday,Benzinga reports. The firm ...

Evercore ISI analyst Kirk Materne maintained a Hold rating on Tyler Technologies (TYL – Research Report) yesterday and set a price target of ...

Evercore ISI analyst Kutgun Maral maintained a Hold rating on Fox (FOXA – Research Report) yesterday and set a price target of $55.00. The ...